Immunomodulatory effects of the Agaricus blazei Murrill-based mushroom extract AndoSan in patients with multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation: a randomized, double blinded clinical study. 2015

Jon-Magnus Tangen, and Anne Tierens, and Jo Caers, and Marilene Binsfeld, and Ole Kristoffer Olstad, and Anne-Marie Siebke Trøseid, and Junbai Wang, and Geir Erland Tjønnfjord, and Geir Hetland
Deparment of Haematology, Oslo University Hospital, 0424 Oslo, Norway ; Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway.

Forty patients with multiple myeloma scheduled to undergo high dose chemotherapy with autologous stem cell support were randomized in a double blinded fashion to receive adjuvant treatment with the mushroom extract AndoSan, containing 82% of Agaricus blazei Murrill (19 patients) or placebo (21 patients). Intake of the study product started on the day of stem cell mobilizing chemotherapy and continued until the end of aplasia after high dose chemotherapy, a period of about seven weeks. Thirty-three patients were evaluable for all study endpoints, while all 40 included patients were evaluable for survival endpoints. In the leukapheresis product harvested after stem cell mobilisation, increased percentages of Treg cells and plasmacytoid dendritic cells were found in patients receiving AndoSan. Also, in this group, a significant increase of serum levels of IL-1ra, IL-5, and IL-7 at the end of treatment was found. Whole genome microarray showed increased expression of immunoglobulin genes, Killer Immunoglobulin Receptor (KIR) genes, and HLA genes in the Agaricus group. Furthermore, AndoSan displayed a concentration dependent antiproliferative effect on mouse myeloma cells in vitro. There were no statistically significant differences in treatment response, overall survival, and time to new treatment. The study was registered with Clinicaltrials.gov NCT00970021.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D007937 Leukapheresis The preparation of leukocyte concentrates with the return of red cells and leukocyte-poor plasma to the donor. Leukocytapheresis,Leukopheresis,Lymphapheresis,Lymphocytapheresis,Leukocytopheresis,Lymphocytopheresis,Lymphopheresis,Leukaphereses,Leukocytaphereses,Leukocytophereses,Leukophereses,Lymphaphereses,Lymphocytaphereses,Lymphocytophereses,Lymphophereses
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression

Related Publications

Jon-Magnus Tangen, and Anne Tierens, and Jo Caers, and Marilene Binsfeld, and Ole Kristoffer Olstad, and Anne-Marie Siebke Trøseid, and Junbai Wang, and Geir Erland Tjønnfjord, and Geir Hetland
January 2017, BioMed research international,
Jon-Magnus Tangen, and Anne Tierens, and Jo Caers, and Marilene Binsfeld, and Ole Kristoffer Olstad, and Anne-Marie Siebke Trøseid, and Junbai Wang, and Geir Erland Tjønnfjord, and Geir Hetland
March 2006, Expert review of anticancer therapy,
Jon-Magnus Tangen, and Anne Tierens, and Jo Caers, and Marilene Binsfeld, and Ole Kristoffer Olstad, and Anne-Marie Siebke Trøseid, and Junbai Wang, and Geir Erland Tjønnfjord, and Geir Hetland
December 2016, Scandinavian journal of immunology,
Jon-Magnus Tangen, and Anne Tierens, and Jo Caers, and Marilene Binsfeld, and Ole Kristoffer Olstad, and Anne-Marie Siebke Trøseid, and Junbai Wang, and Geir Erland Tjønnfjord, and Geir Hetland
February 2013, Current oncology (Toronto, Ont.),
Jon-Magnus Tangen, and Anne Tierens, and Jo Caers, and Marilene Binsfeld, and Ole Kristoffer Olstad, and Anne-Marie Siebke Trøseid, and Junbai Wang, and Geir Erland Tjønnfjord, and Geir Hetland
January 2016, PloS one,
Jon-Magnus Tangen, and Anne Tierens, and Jo Caers, and Marilene Binsfeld, and Ole Kristoffer Olstad, and Anne-Marie Siebke Trøseid, and Junbai Wang, and Geir Erland Tjønnfjord, and Geir Hetland
January 2016, PloS one,
Jon-Magnus Tangen, and Anne Tierens, and Jo Caers, and Marilene Binsfeld, and Ole Kristoffer Olstad, and Anne-Marie Siebke Trøseid, and Junbai Wang, and Geir Erland Tjønnfjord, and Geir Hetland
March 2015, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Jon-Magnus Tangen, and Anne Tierens, and Jo Caers, and Marilene Binsfeld, and Ole Kristoffer Olstad, and Anne-Marie Siebke Trøseid, and Junbai Wang, and Geir Erland Tjønnfjord, and Geir Hetland
March 2019, Leukemia & lymphoma,
Jon-Magnus Tangen, and Anne Tierens, and Jo Caers, and Marilene Binsfeld, and Ole Kristoffer Olstad, and Anne-Marie Siebke Trøseid, and Junbai Wang, and Geir Erland Tjønnfjord, and Geir Hetland
September 2001, Mutation research,
Jon-Magnus Tangen, and Anne Tierens, and Jo Caers, and Marilene Binsfeld, and Ole Kristoffer Olstad, and Anne-Marie Siebke Trøseid, and Junbai Wang, and Geir Erland Tjønnfjord, and Geir Hetland
April 2017, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,
Copied contents to your clipboard!